Skip to main content
OpenTrials

Clinical trial condition

Hypersensitivity, Immediate

Explore clinical trials studying Hypersensitivity, Immediate. Study availability and eligibility vary by location and protocol.

6,736 public trials 631 recruiting studies
Refine in advanced search Browse all conditions

Hypersensitivity, Immediate trial results

Completed

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

NCT01430403

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • National Jewish Health Denver, Colorado, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Children's Memorial Hospital - Department of Allergy Chicago, Illinois, United States
  • Boston University School of Medicine Boston, Massachusetts, United States
View Trial Details
Completed

Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler

NCT02416180

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Frankfurt am Main, Hesse, Germany
  • GSK Investigational Site Frankfurt am Main, Hesse, Germany
  • GSK Investigational Site Neu-Isenburg, Hesse, Germany
  • GSK Investigational Site Reinfeld, Schleswig-Holstein, Germany
View Trial Details
Completed

A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma

NCT01978119

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Nizhny Novgorod, Russia
  • GSK Investigational Site Penza, Russia
  • GSK Investigational Site Ryazan, Russia
  • GSK Investigational Site Smolensk, Russia
View all 13 locations
View Trial Details
Completed

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

NCT02094937

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Aomori, Japan
  • GSK Investigational Site Fukuoka, Japan
  • GSK Investigational Site Fukuoka, Japan
  • GSK Investigational Site Fukuoka, Japan
View all 33 locations
View Trial Details

Related conditions